Which immunotherapy product, launched in 2014, became the first PD-1 inhibitor approved for cancer treatment and generated over $1 billion in sales within its first year on the market?

In the competitive landscape of pharmaceutical innovations, certain product launches fundamentally transform treatment paradigms and establish new standards of care. This poll tests your knowledge about one of the most significant cancer therapy breakthroughs of the 2010s - a product that not only revolutionized treatment but also represented a landmark achievement in targeted immunotherapy development. Do you know which groundbreaking medicine this question refers to?

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Keytruda (pembrolizumab) by Merck
Opdivo (nivolumab) by Bristol-Myers Squibb
Tecentriq (atezolizumab) by Roche
Imfinzi (durvalumab) by AstraZeneca